Nature Medicine commentary calls for joint governance of embryo editing and selection

A Nature Medicine commentary calls for joint governance of embryo editing and embryo selection, highlighting the intersection of advances in base editing and commercial reproductive genomics. The article discusses early human embryo research rather than reporting a clinical trial; the available preview provides no sample sizes or quantitative efficacy estimates.

The authors cite a preprint by Jerabek and colleagues reporting adenine base editing at two targets without the major chromosomal abnormalities observed in some earlier experiments. They also cite a Nature study by Bower and colleagues that used base editing to establish a functional knockout of a developmental regulator in early human embryogenesis. Although these findings represent research advances, the commentary stresses that they do not establish a clinical indication for heritable genome editing.

The authors contrast preimplantation genetic testing for chromosomal abnormalities and serious monogenic disorders with commercial offerings of whole-genome embryo profiling and polygenic ranking for common diseases and some non-clinical traits. They cite an American Society for Reproductive Medicine opinion concluding that testing for polygenic disorders is not ready for clinical use because of uncertain predictive value and substantial ethical concerns. This is a governance argument, not evidence of clinical benefit; only a subscription preview was available, and one cited editing study is a preprint. The authors declare no competing interests.